Physician profile
Daniel Kesden
NPI 1851365142
$6,394.58
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,638 · 2020: $669 · 2021: $772 · 2022: $1,130 · 2023: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $185.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,630.69 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,206.78 | 2019-2022 | |
| Atricure, INC. | $1,046.97 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $683.45 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $539.00 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $334.88 | 2019-2020 | |
| Abbott Laboratories | $316.48 | 2019-2022 | |
| Edwards Lifesciences Corporation | $155.20 | 2019 | |
| Abiomed | $132.74 | 2022 | |
| Ethicon US, LLC | $113.64 | 2019 | |
| Boston Scientific Corporation | $108.97 | 2019 | |
| Medtronic Vascular, INC. | $38.39 | 2020 | |
| Merck Sharp & Dohme LLC | $28.05 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $20.52 | 2023 | Camzyos |
| Pfizer INC. | $20.16 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $18.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kesden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.